Temozolomide Dry Granules for Stability and Uniformity
Solution Overview
Problem
Temozolomide, an anti-cancer drug, is water-insoluble and unstable under wet conditions, high pH, and temperature, leading to degradation and difficulty in achieving uniform content in capsule formulations due to its bulky volume and low flowability.
Innovation Solution
The development of dry granules containing temozolomide and tartaric acid as a pH stabilizer, combined with anti-caking agents and other pharmaceutically acceptable additives, using a dry-granulation method to enhance stability, flowability, and uniformity, while maintaining the dissolution pattern of conventional formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If temozolomide is used in capsule formulation, then high dosage per capsule is achieved, but uniform content is difficult to achieve due to bulky volume and low flowability
Solution Approach 1:
The temozolomide powder is segmented into granules with specific size ranges (0.5-3.0mm) through granulation processes. This segmentation transforms the bulky powder into discrete particles with improved flow characteristics, enabling uniform distribution and accurate dosing in capsule formulations while maintaining high drug content.
Solution Approach 2:
The physical parameters of temozolomide are changed by converting it from fine powder to granulated form with controlled size distribution. This parameter change in particle morphology and size improves flowability and fill uniformity, resolving the contradiction between high dosage and content uniformity in capsule formulations.
2Ease of operation
If temozolomide is stored under wet conditions or high temperature, then dissolution may be enhanced, but stability deteriorates leading to degradation
Solution Approach 1:
The granules are formulated with pH stabilizers and protective excipients that create a localized stable environment around the temozolomide particles. This local quality control maintains drug stability during storage under various conditions while allowing controlled dissolution when the capsule is administered, as the protective matrix breaks down in the gastrointestinal environment.
Solution Approach 2:
The formulation includes stabilizers and protective agents that are incorporated beforehand into the granule structure. These protective components cushion the temozolomide against degradation from moisture and heat during storage, preventing stability deterioration while maintaining the ability to dissolve when needed for therapeutic effect.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
Disclosed are dry granules comprising temozolomide and tartaric acid as a pH stabilizer, a pharmaceutical composition including the dry granules with improved stability and a method of preparing the same.